Jonathan W Haft

Concordia University–Ann Arbor, Ann Arbor, Michigan, United States

Are you Jonathan W Haft?

Claim your profile

Publications (81)297.7 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: Centrifugal pumps are increasingly used for extracorporeal membrane oxygenation (ECMO) rather than roller pumps. However, shear forces induced by these types of continuous flow pumps are associated with acquired von Willebrand Factor deficiency and bleeding complications. This study was undertaken to compare adverse bleeding complications with use of centrifugal and roller pumps in patients on prolonged ECMO support. The records of all adult ECMO patients from June 2002 to 2013 were retrospectively reviewed using the University of Michigan Health System database and the Extracorporeal Life Support Organization registry, focusing on patients supported for at least 5 days. Ninety-five ECMO patients met criteria for inclusion (48 roller vs. 47 centrifugal pump). Indications included pulmonary (79%), cardiac (15%), and extracorporeal cardiopulmonary resuscitation (6%), without significant difference between the two groups. Despite lower heparin anticoagulation (10.9 vs. 13.7 IU/kg/hr) with centrifugal pumps, there was a higher incidence of non-surgical bleeding (gastrointestinal, pulmonary, and neurological) in centrifugal pump patients (26.1 vs. 9.0 events/1000 patient-days, p = 0.024). In conclusion, in our historical comparison, despite reduced anti-coagulation, ECMO support using centrifugal pumps was associated with a higher incidence of non-surgical bleeding. The mechanisms behind this are multifactorial and require further investigation.
    ASAIO journal (American Society for Artificial Internal Organs: 1992) 04/2015; DOI:10.1097/MAT.0000000000000243 · 1.39 Impact Factor
  • The Journal of Heart and Lung Transplantation 04/2015; 34(4):S290. DOI:10.1016/j.healun.2015.01.811 · 5.61 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Inhaled nitric oxide (iNO) is a rescue treatment for severe hypoxemia in the intensive care unit setting. To evaluate the effectiveness and safety of iNO in adult patients with severe hypoxemia before and during transport to a tertiary care center. Prospective data were examined in a retrospective cohort study. Patients with severe hypoxemia and cardiopulmonary failure (n=139) at referring hospitals in whom conventional therapy was unsuccessful were treated with iNO in the intensive care units in anticipation of transfer to a tertiary center. Treatment wih iNO was initiated by the critical care transport team in 114 patients and continued in 25 patients. Arterial blood gas analysis was done before and after iNO treatment. Patients treated with iNO had significant improvement in oxygenation: mean (SD) for PaO2 increased from 60.7 (20.2) to 72.3 (40.6) mm Hg (P=.008), and mean (SD) for ratio of PaO2 to fraction of inspired oxygen (P:F) increased from 62.4 (26.1) to 73.1 (42.6) (P= .03). Use of iNO was continued through transport in 102 patients, all of whom were transported without complication. The P:F continued to improve, with a mean (SD) of 109.7 (73.8) from 6 to 8 hours after arrival at the tertiary center (P< .001 relative to values both before and after treatment). Among patients treated with iNO, 60.2% survived to discharge. In 35 nonresponders, iNO was discontinued, and 15 patients could not be transferred owing to life-threatening hypoxemia; 2 were later transferred on extracorporeal membrane oxygenation. Of 18 patients transported without iNO, 9 (50%) survived. Use of iNO significantly improves oxygenation of patients with severe hypoxemia and allows safe transfer to a tertiary care center. (American Journal of Critical Care. 2015; 24:110-117). ©2015 American Association of Critical-Care Nurses.
    American Journal of Critical Care 03/2015; 24(2):110-7. DOI:10.4037/ajcc2015570 · 1.60 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The usual duration of ECMO in patients with severe acute respiratory distress syndrome (ARDS) is 7-10 days. Prolonged duration ECMO (defined as > 14 days) is increasingly being documented with native lung recovery or as a bridge to lung transplantation. We report a case of prolonged duration ECMO (6,364 hours, 265 days) requiring no complete circuit exchange. As critical care improves, prolonged ECMO will continue to pose unique technological and ethical challenges that test our expectations of this treatment modality. There is a critical need for diagnostic modalities to provide objective assessment of native lung recovery in patients requiring prolonged duration ECMO.
    ASAIO journal (American Society for Artificial Internal Organs: 1992) 11/2014; 61(2). DOI:10.1097/MAT.0000000000000181 · 1.39 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This is a review of the University of Michigan experience with extracorporeal life support (ECLS) also known as extracorporeal membrane oxygenation (ECMO). Two thousand patients were managed with ECMO from 1973-2010. The first thousand were reported previously.Of the 2000 patients, 74% and were weaned from ECLS, and 64% survived to hospital discharge In patients with respiratory failure, survival to hospital discharge was 84% in 799 neonates, 76% in 239 children, and 50% in 353 adults. Survival in patients with cardiac failure was 45% in 361 children, and 38% in 119 adults. ECLS during cardiac arrest (ECPR) was performed in 129 patients, with 41% surviving to discharge. Survival decreased from 74% to 55% between the first and second thousand patients. The most common complication was bleeding at sites other than the head, with an incidence of 39%, and the least frequent complication was pump malfunction, with a 2% incidence. Intracranial bleeding or infarction occurred in 8% of patients, with a 43% survival rate. This is the largest series of ECLS at one institution reported in the world to date. Our experience has shown that ECLS saves lives of moribund patients with acute pulmonary and cardiac failure in all age groups.
    ASAIO journal (American Society for Artificial Internal Organs: 1992) 09/2014; 61(1). DOI:10.1097/MAT.0000000000000150 · 1.39 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background. Interfacility transport of patients on extracorporeal membrane oxygenation (ECMO) has been performed in large numbers at only a few programs. Limited data are available on outcomes after ECMO transport to justify expanding or discontinuing these programs. Methods. This was a retrospective review of a 20-year, single-institution experience with interhospital ECMO transport as well as a systematic review of reports of transfers of patients on ECMO. Results of both were compared with historical data from the international registry of the Extracorporeal Life Support Organization (ELSO). Results. Between 1990 and 2012, ECMO was used to facilitate transport of 221 patients to our institution, and 135 (62%) survived to discharge. Review of an additional 27 case series describing ECMO transport of 643 patients showed an overall survival of 61%. After stratifying by age and primary indication for ECMO, survival of transported patients was not significantly different compared with all ECMO patients in the ELSO registry, with the exception of pediatric patients treated for respiratory failure (transported patients in this category had higher survival than those in the ELSO registry). Conclusions. Interfacility transport on ECMO is feasible and can be accomplished safely in the critically ill. Survival of transported patients is comparable to age-matched and treatment-matched ECMO patients at large. (C) 2014 by The Society of Thoracic Surgeons
    The Annals of Thoracic Surgery 08/2014; 98(4). DOI:10.1016/j.athoracsur.2014.06.025 · 3.63 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract BACKGROUND: Centrifugal pumps are used increasingly for temporary mechanical support for the treatment of cardiogenic shock. However, centrifugal pumps can generate excessive negative pressure and are afterload sensitive. A previously developed modified roller pump mitigates these limitations both in vitro and in preliminary animal experiments. We report the results of intermediate-term testing of our evolving pump technology, known as the BioVAD. METHODS: The BioVAD was implanted in 6 adult male sheep (62.5 ± 3.9 kg), with drainage from the left atrium and reinfusion into the descending aorta. The sheep were monitored for 5 days. Heparin was given during the initial implantation, but no additional anticoagulants were given. Data collected included hemodynamic status, pump flow and pressures, laboratory values to monitor end-organ function and hemolysis, pathologic specimens to evaluate for thromboembolic events and organ ischemia, and explanted pump evaluation results. RESULTS: All animals survived the planned experimental duration and there were no pump malfunctions. Mean BioVAD flow was 3.57 ± 0.30 L/min (57.1 mL/kg/min) and mean inlet pressure was -30.51 ± 4.25 mm Hg. Laboratory values, including plasma free hemoglobin, creatinine, lactate, and bilirubin levels, remained normal. Three animals had small renal cortical infarcts, but there were no additional thromboembolic events or other abnormalities seen on pathologic examination. No thrombus was identified in the BioVAD blood flow path. CONCLUSIONS: The BioVAD performed well for 5 days in this animal model of temporary left ventricular assistance. Its potential advantages over centrifugal pumps may make it applicable for short-term mechanical circulatory support.
    The Annals of Thoracic Surgery 07/2014; 98(1):97-102. DOI:10.1016/j.athoracsur.2014.04.027 · 3.63 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Although left ventricular assist device (LVAD) management strategies are undertaken to reduce the development of aortic insufficiency (AI), the effect of AI on patient morbidity and mortality is not known.
    The Journal of Heart and Lung Transplantation 06/2014; 33(12). DOI:10.1016/j.healun.2014.06.008 · 5.61 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Postcardiotomy shock affects 0.5% to 6% of cardiac operations and is associated with a high mortality. Many of these patients had their procedures performed at lower-volume cardiac surgery centers with limited resources. The objective of this study was to determine the outcomes in patients in postcardiotomy shock who were transferred to a tertiary care center for escalated care. We performed a retrospective review of 104 postcardiotomy shock patients transferred to our institution between 2004 and 2012. Univariable and multivariable analyses were performed to determine predictors of in-hospital and overall survival. Seventy-eight percent of patients were receiving temporary mechanical support. The in-hospital mortality in our series was 46%. Multivariable predictors of in-hospital mortality included higher initial creatinine level on arrival and a history of known heart failure. Multivariable predictors of overall mortality included higher initial creatinine and lactate levels, lower initial ejection fraction, and a history of heart failure and hypertension. The Kaplan-Meier estimation of 5-year survival was 39% in all patients and 72% in patients who survived to hospital discharge. Patients with postcardiotomy cardiac failure transported to a tertiary care center for advanced cardiac support had a nearly 50% survival, with excellent long-term survival of those discharged alive. Preservation of end-organ function, often with mechanical support, can improve survival.
    The Annals of thoracic surgery 05/2014; 98(1). DOI:10.1016/j.athoracsur.2013.12.091 · 3.65 Impact Factor
  • European Heart Journal 04/2014; 35(31). DOI:10.1093/eurheartj/ehu135 · 14.72 Impact Factor
  • The Journal of Heart and Lung Transplantation 04/2014; 33(4):S132. DOI:10.1016/j.healun.2014.01.354 · 5.61 Impact Factor
  • The Journal of Heart and Lung Transplantation 04/2014; 33(4):S196-S197. DOI:10.1016/j.healun.2014.01.535 · 5.61 Impact Factor
  • The Journal of Heart and Lung Transplantation 04/2014; 33(4):S216-S217. DOI:10.1016/j.healun.2014.01.559 · 5.61 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: It has been suggested that pulsatile blood flow is superior to continuous flow in cardiopulmonary bypass (CPB). However, adoption of pulsatile flow (PF) technology has been limited due to practically and complexity of creating a consistent physiologic pulse. A pediatric pulsatile rotary ventricular pump (PRVP) was designed to address this problem. We evaluated the PRVP in an animal model, and determined its ability to generate PF during CPB.The PRVP (modified peristaltic pump, with tapering of the outlet of the pump chamber) was tested in 4 piglets (10-12kg). Cannulation was performed with right atrial and aortic cannulae, and pressure sensors were inserted into the femoral arteries. Pressure curves were obtained at different levels of flow and compared with both the animal's baseline physiologic function and a continuous flow (CF) roller pump.Pressure and flow waveforms demonstrated significant pulsatility in the PRVP setup compared to CF at all tested conditions. Measurement of hemodynamic energy data, including the percent pulsatile energy and the surplus hydraulic energy, also revealed a significant increase in pulsatility with the PRVP (p <0.001).PRVP creates physiologically significant PF, similar to the pulsatility of a native heart, and has the potential to be easily implemented in pediatric CPB.
    ASAIO journal (American Society for Artificial Internal Organs: 1992) 03/2014; 60(3). DOI:10.1097/MAT.0000000000000058 · 1.39 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The optimal management of functional tricuspid regurgitation (FTR) in the setting of mitral valve operations remains controversial. The objective of this study is to compare the outcomes of congestive heart failure patients who underwent a prophylactic tricuspid operation for FTR as a component of their initial mitral valve procedure with those who underwent a redo tricuspid operation at a later date for residual FTR. Patients with FTR repaired as a redo operation between 2004 and 2012 were identified. These patients were propensity-matched 1:2 with contemporaneous patients with FTR or tricuspid dilatation who underwent tricuspid repair at the same time as mitral valve repair. Demographic information, postoperative complications, and short-term and long-term mortality rates were compared between groups. There were 21 patients treated with redo tricuspid valve repair matched with 42 patients treated prophylactically. There were 3 deaths at 30 days in the redo group (14%), compared with zero in the prophylactic group (p = 0.03). Overall long-term mortality in the redo group was 29% (6 of 21), with a mean 31 months of follow-up, but was only 14% (6 of 42) in the prophylactic group, with a mean 25 months of follow-up. Kaplan-Meier long-term survival analysis did not reveal a difference between groups (log-rank p = 0.37) once the perioperative period was survived. Redo tricuspid valve repair for residual FTR can be performed with acceptable short-term and long-term mortality. However, treatment of FTR at the time of the initial intervention should be considered, because it is safe and effective. A randomized, controlled trial of prophylactic tricuspid operation for FTR at the time of the mitral operation may be warranted.
    The Annals of thoracic surgery 02/2014; 97(5). DOI:10.1016/j.athoracsur.2013.11.049 · 3.65 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background While left ventricular assist device (LVAD) management strategies are undertaken to reduce aortic insufficiency (AI) development, the impact of AI on patient morbidity and mortality is not known. Methods Patients undergoing HeartMate II implant were prospectively followed with serial echocardiograms. Kaplan-Meier methods and log rank testing were used to estimate and compare mortality and freedom from ≥moderate right ventricular hypokinesis (RVHK), ≥moderate mitral regurgitation (MR), and hemolysis based on AI severity. Mixed modelling was used to examine for correlates of AI development in the pre- and post-operative setting and to investigate impact of AI on postoperative MR and RVHK. Results There were 930 echocardiograms completed on 166 patients. During 291 person-years of follow-up, ≥mild-moderate AI developed in 70 (0.38 persons per year (PPY)), ≥moderate AI in 36 (0.17 PPY), ≥moderate to severe AI in 11 (0.039 PPY), and ≥severe AI in 2 (0.0069 PPY). Overall 2 YR survival and 2 YR survival following onset of ≥moderate AI was 87±6.2% and 65±11%, respectively, compared with 76±5.1% and 76±5.1%, respectively in those with less AI (p=0.57). Patients with moderate AI were not more likely to develop MR, hemolysis events or worsening RVHK, but patients with preexisting RVHK appeared to be less tolerant of AI. Three of 35 deaths could be directly attributed to AI and no reoperations were performed solely for AI. Conclusions AI is common after LVAD implant but did not impact survival in this cohort. Except in those with significant RV dysfunction, this calls into question need for echocardiogram guided device settings to ensure aortic valve opening.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The clinical relevance of elevated serum markers of hemolysis during left ventricular assist device (LVAD) support has not been fully ascertained. Lactate dehydrogenase (LDH) and serum free hemoglobin (sfHg) values were tallied monthly in 182 patients on HeartMate II (Thoratec, Pleasanton, CA) LVAD support. Peak values for each marker were identified, and 2 hemolysis definitions were applied to the cohort: Hemolysis according to Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) criteria (sfHg > 40 mg/dl with signs/symptoms) and/or hemolysis defined by an LDH ≥ 600 IU/liter (2.5-times the upper limit of laboratory normal). Kaplan-Meier survival free from death, urgent United Network of Organ Sharing 1A transplant for thrombosis, device exchange for thrombosis, and stroke/peripheral embolism was estimated, and Cox hazard ratios (HR) with the 95% confidence interval (95% CI) were calculated. Areas under the receiver-operating characteristic curves (AUCs) for predicting 1-year event-free survival were calculated. Hemolysis occurred in 32 patients (18%) by INTERMACS criteria and in 68 (37%) patients by LDH criteria. Over a median (25(th), 75(th)) support of 427 days (245, 793 days), there were 78 events. One year event-free survival after the onset of INTERMACS-defined hemolysis was 16% ± 8.3% compared with 85% ± 3.2% in non-hemolyzers (HR, 14.7; 95% CI, 7.9-27; AUC 0.70 ± 0.05; p < 0.001; ). One year event-free survival after the onset of LDH-defined hemolysis was 32% ± 7.2% compared with 89% ± 3.2% in those with persistent LDH values < 600 IU/liter (HR, 8.0; 95% CI, 4.4-14; AUC 0.87 ± 0.04; p < 0.001). Patients who met the LDH hemolysis definition had longer times from hemolysis onset to clinical events and larger magnitudes of risk for embolism and device exchange for thrombosis than those with INTERMACS hemolysis. Serum hemolysis marker elevations are associated with increased events in LVAD patients. LDH monitoring provides an earlier diagnosis of adverse events than sfHg, supporting need for a new INTERMACS definition of VAD-associated hemolysis.
    The Journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation 01/2014; 33(1):35-43. DOI:10.1016/j.healun.2013.08.021 · 5.61 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Extracorporeal membrane oxygenation (ECMO) is recommended as a treatment modality for severe acute respiratory distress syndrome (PaO2/FiO2 ≤ 100 mm Hg with positive end-expiratory pressure ≥ 5 cm H2O) as defined by the Berlin definition. The reported usual duration of ECMO in these patients is 7-10 days. However, increasing reports of prolonged duration ECMO (>14 days) for respiratory failure document survival rates of 50-70% with native lung recovery, and ECMO bridge to lung transplantation has been performed at many centers. At present, there are no established national criteria for when to consider futility or lung transplantation in adult patients requiring ECMO for acute respiratory failure. We report a case of prolonged duration venovenous-ECMO (1,347 hours, 56.13 days), with native lung recovery and discuss treatment strategies to optimize native lung recovery in ECMO patients. The lung may have unexpected regenerative capacity with native lung recovery after prolonged mechanical support, similar to acute kidney injury and native renal recovery. We recommend redefining irreversible lung injury and futility in ECMO.
    ASAIO journal (American Society for Artificial Internal Organs: 1992) 11/2013; 59(6):642-50. DOI:10.1097/MAT.0b013e3182a9e341 · 1.39 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This study evaluated the effectiveness of an atrial septal defect (ASD) with venovenous extracorporeal membrane oxygenation (vv-ECMO) as a bridge to transplantation. Sheep (56 ± 3 kg; n = 7) underwent a right-sided thoracotomy to create the ASD (diameter = 1 cm) and place instrumentation and a pulmonary artery (PA) occluder. After recovery, animals were placed on ECMO, and the PA was constricted to generate a twofold rise in right ventricular (RV) systolic pressure. Sheep were then maintained for 60 hours on ECMO, and data were collected hourly. Five sheep survived 60 hours. One sheep died because of a circuit clot extending into the RV, and another died presumably because of an arrhythmia. Mean right ventricular pressure (mRVP) was 19 ± 3 mm Hg at baseline, averaged 27 ± 7 mm Hg over the experiment, but was not statistically significant (p = 0.27) due to one sheep without an increase. Cardiac output was 6.8 ± 1.2 L/min at baseline, averaged 6.0 ± 1.0 L/min during the experiment, and was statistically unchanged (p = 0.34). Average arterial oxygen saturation and PCO2 over the experiment were 96.8 ± 1.4% and 31.8 ± 3.4 mm Hg, respectively. In conclusion, an ASD combined with vv-ECMO maintains normal systemic hemodynamics and arterial blood gases during a long-term increase in RV afterload.
    ASAIO journal (American Society for Artificial Internal Organs: 1992) 11/2013; 59(6):558-63. DOI:10.1097/MAT.0b013e3182a91ddb · 1.39 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To determine the impact of coronary computed tomography angiography (CCTA) on treatment decisions made by cardiac surgeons and to explore barriers to implementation of CCTA as first-line imaging workup before coronary artery bypass. Tertiary academic medical center retrospective cohort study. Questionnaires administered to three cardiac surgeons regarding diagnosis and treatment decisions with level of confidence in decision making for 30 chest pain patients, after reviewing deidentified catheter coronary angiogram (CCA) and CCTA images on the same patients, several weeks apart. All surgeons tended to report more severe disease with CCTA than CCA (P < .05). Treatment decisions differed in 12 (40%), 14 (47%), and 18 (60%) patients within each individual surgeon based on CCTA images compared to CCA images (P = .11, .01, and .02, respectively). Confidence levels were significantly higher with CCA for the diagnosis and treatment of coronary artery disease for all three surgeons (P < .05). There was a tendency toward more invasive treatment choices (angioplasty, stent insertion, or coronary artery bypass graft) when making treatment decisions based upon CCTA images. Severity of disease may be overestimated by cardiac surgeons when using CCTA as a decision-making test, tending toward more invasive treatment choices compared to CCA. Additionally, cardiac surgeons may be more confident with their diagnosis and treatment based on CCA. These may be important limitations in the application of CCTA in clinical practice and may reflect the maturation of CCTA use in practice, diffusion of the technology and/or a reflection of the technology itself.
    Academic radiology 09/2013; 20(9):1083-90. DOI:10.1016/j.acra.2013.05.008 · 2.08 Impact Factor

Publication Stats

716 Citations
297.70 Total Impact Points


  • 2002–2014
    • Concordia University–Ann Arbor
      Ann Arbor, Michigan, United States
    • University of Michigan
      • • Department of Surgery
      • • Department of Cardiac Surgery
      • • Section of Vascular Surgery
      Ann Arbor, Michigan, United States